{"id":"cyclophosphamide-cyc","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"60-90","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Alopecia"},{"rate":"5-40","effect":"Hemorrhagic cystitis"},{"rate":"variable","effect":"Infertility (gonadal dysfunction)"},{"rate":"1-5","effect":"Secondary malignancies"},{"rate":"common","effect":"Immunosuppression and infection risk"},{"rate":"1-5","effect":"Cardiotoxicity (at high doses)"}]},"_chembl":{"chemblId":"CHEMBL1200796","moleculeType":"Small molecule","molecularWeight":"279.10"},"_dailymed":{"setId":"1d3396d8-4c03-4a28-890a-d87c6c53a74e","title":"CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION [BLUEPOINT LABORATORIES]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is a nitrogen mustard derivative that acts as a prodrug, requiring hepatic activation to form active metabolites. These metabolites bind to DNA and form inter- and intra-strand cross-links, disrupting DNA replication and transcription. It is used both as a cytotoxic chemotherapy agent and as an immunosuppressant at lower doses due to its ability to deplete lymphocytes.","oneSentence":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cell death in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:29.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphomas (Hodgkin and non-Hodgkin)"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Lung cancer"},{"name":"Leukemias"},{"name":"Multiple myeloma"},{"name":"Severe rheumatoid arthritis (immunosuppressive use)"},{"name":"Systemic lupus erythematosus (immunosuppressive use)"}]},"trialDetails":[{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":"Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)","enrollment":100},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT03936829","phase":"NA","title":"Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-04-28","conditions":"Lipodystrophy Acquired, Type1diabetes","enrollment":10},{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome","enrollment":50},{"nctId":"NCT06152172","phase":"PHASE1","title":"CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Porter","startDate":"2024-08-05","conditions":"Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis","enrollment":24},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06451159","phase":"PHASE1","title":"A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bruce Cree","startDate":"2024-06-20","conditions":"Progressive Multiple Sclerosis","enrollment":10},{"nctId":"NCT06680349","phase":"PHASE4","title":"Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2022-12-01","conditions":"Fibrillary Glomerulonephritis","enrollment":21},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":"Wegener's Granulomatosis, Vasculitis","enrollment":84},{"nctId":"NCT01895244","phase":"PHASE2","title":"Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2012-09","conditions":"Scleroderma, Cardiac Involvement, Autologous Stem Cell Transplantation","enrollment":44},{"nctId":"NCT02684708","phase":"PHASE3","title":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Giessen","startDate":"2015-10-01","conditions":"Classical Hodgkin Lymphoma","enrollment":2200},{"nctId":"NCT01088750","phase":"PHASE4","title":"Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2009-11-01","conditions":"Lymphoma","enrollment":225},{"nctId":"NCT03096275","phase":"PHASE3","title":"Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis","status":"COMPLETED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2017-03-16","conditions":"Takayasu Arteritis","enrollment":138},{"nctId":"NCT02727387","phase":"PHASE2","title":"Protocol for the Treatment of Metastatic Ewing Sarcoma","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2009-06-01","conditions":"Ewing's Sarcoma (ES)","enrollment":155},{"nctId":"NCT05495893","phase":"PHASE4","title":"MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2022-07-25","conditions":"Mycophenolate Mofetil, Cyclophosphamide, Lupus Nephritis","enrollment":224},{"nctId":"NCT02460588","phase":"PHASE3","title":"Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":120},{"nctId":"NCT05195086","phase":"","title":"A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt","status":"COMPLETED","sponsor":"Nada Magdy Mansour","startDate":"2018-07-01","conditions":"Lupus Nephritis","enrollment":122},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Sjogren's Syndrome","enrollment":240},{"nctId":"NCT00433459","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2007-01","conditions":"Lymphoma","enrollment":2134},{"nctId":"NCT02046070","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-03-05","conditions":"Multiple Myeloma","enrollment":148},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT03200002","phase":"PHASE2","title":"Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis","status":"COMPLETED","sponsor":"Chitwan Medical College","startDate":"2014-01-01","conditions":"To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients","enrollment":49},{"nctId":"NCT01257802","phase":"PHASE3","title":"GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases","status":"TERMINATED","sponsor":"Joseph Mccune","startDate":"2011-05","conditions":"Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System","enrollment":14},{"nctId":"NCT00482911","phase":"PHASE2","title":"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-04","conditions":"Intraocular Melanoma, Malignant Conjunctival Neoplasm","enrollment":12},{"nctId":"NCT01072773","phase":"PHASE2","title":"Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":"Primary Systemic Amyloidosis","enrollment":2},{"nctId":"NCT02027220","phase":"PHASE2","title":"Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2013-12","conditions":"Myeloma, Bortezomib, Cyclophosphamide","enrollment":60},{"nctId":"NCT01646736","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-07","conditions":"Nephritis, Lupus","enrollment":130},{"nctId":"NCT01207297","phase":"PHASE1","title":"Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2003-03","conditions":"SLE, Lupus Nephritis, Renal Insufficiency","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":789,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cyclophosphamide (CYC)","genericName":"Cyclophosphamide (CYC)","companyName":"Hansa Biopharma AB","companyId":"hansa-biopharma-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cell death in rapidly dividing cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Breast cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}